Introduction {#tca12783-sec-0005}
============

Non‐small cell lung cancer (NSCLC) is one of the most common clinically diagnosed malignant carcinomas. It is estimated that 234 030 new cases and 154 050 deaths from NSCLC will occur in the United States in 2018.[1](#tca12783-bib-0001){ref-type="ref"} The general prognosis of NSCLC is poor, particularly in advanced‐stage patients, with an extremely low five‐year survival rate. One of the major reasons for this poor prognosis is the lack of effective lung cancer screening or early diagnostic methods.[2](#tca12783-bib-0002){ref-type="ref"} Several studies have evaluated lung cancer screening methods such as X‐ray,[3](#tca12783-bib-0003){ref-type="ref"}, [4](#tca12783-bib-0004){ref-type="ref"} sputum cytology, and chest computed tomography (CT);[5](#tca12783-bib-0005){ref-type="ref"} however, such methods yield low sensitivity or specificity and thus are not adequate to diagnose NSCLC at an early stage.

Promoter methylation of tumor suppressor genes is frequently detected in cancer tissue and body fluid in malignant carcinomas such as lung,[6](#tca12783-bib-0006){ref-type="ref"}, [7](#tca12783-bib-0007){ref-type="ref"} colorectal,[8](#tca12783-bib-0008){ref-type="ref"} and esophageal cancers. Previous studies have reported that methylation of the *P16* ^*INK4a*^ gene promoter is common in lung cancer. The methylation frequency of *P16* ^*INK4a*^ in serum or bronchoalveolar fluid (BAF)/sputum in lung cancer patients has been widely discussed; however, the exact diagnostic performance of *P16* ^*INK4a*^ as a biomarker for NSCLC remains inconclusive. Therefore, we conducted this updated meta‐analysis to further evaluate the diagnostic performance of *P16* ^*INK4a*^ as a biomarker for NSCLC.

Methods {#tca12783-sec-0006}
=======

Electronic database search strategy {#tca12783-sec-0007}
-----------------------------------

Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chinese Biomedical Literature databases for studies relevant to *P16* ^*INK4a*^ gene promoter methylation in serum or BAF/sputum. The following keywords were used: non‐small cell lung cancer; non‐small cell carcinoma, NSCLC, *P16*, *P16* ^*INK4a*^; cyclin‐dependent kinase inhibitor 2A, CDKN2A; CDK4 inhibitor; multiple tumor suppressor 1; TP16; methylation; and hypermethylation. Relevant studies were identified and duplicated publications or data were excluded. The title and abstract were then reviewed to locate relevant studies. All potentially suitable studies were reviewed in full‐text and all references of included publications were further screened to identify additional relevant publications. The publication search process is demonstrated in Figure [1](#tca12783-fig-0001){ref-type="fig"}.

![Publication search process.](TCA-9-1032-g009){#tca12783-fig-0001}

Inclusion and exclusion criteria {#tca12783-sec-0008}
--------------------------------

The identified studies were further reviewed to assess whether the inclusion criteria were fulfilled: (i) diagnostic studies relevant to *P16* ^*INK4a*^ promoter methylation and NSCLC; (ii) NSCLC diagnosis confirmed by pathology or cytology; (iii) *P16* ^*INK4a*^ gene promoter methylation was detected by methylation‐specific PCR (MSP), real‐time MSP (RT‐MSP), or quantitative MSP (q‐MSP); (iv) *P16* ^*INK4a*^ gene methylation status in serum or BAF/sputum in NSCLC and control subjects was available for each included study. The exclusion criteria were: (i) case reports or literature reviews; (ii) *P16* ^*INK4a*^ gene methylation status detected in other specimens, not in serum or BAF/sputum; (iii) studies published in languages other than English or Chinese; and (iv) insufficient data to calculate sensitivity and specificity.

Statistical analysis {#tca12783-sec-0009}
--------------------

The diagnostic sensitivity, specificity, and symmetric receiver operating characteristic (SROC) curve were pooled by fixed or random effects method according to the statistical heterogeneity across the included studies. Diagnostic sensitivity and specificity were calculated using the following equations: sensitivity = true positive/(true positive + false negative); specificity = true negative/(true negative + false positive). Publication bias was evaluated by Egger\'s line regression test and Begger\'s funnel plot. *P* \< 0.05 was considered to indicate significant statistical difference.

Results {#tca12783-sec-0010}
=======

Study characteristics {#tca12783-sec-0011}
---------------------

Initially, 488 relevant publications were identified. After reviewing the title, abstract, and full text, 26 studies relevant to *P16* ^*INK4a*^ gene promoter methylation as a biomarker for the diagnosis of NSCLC were included for quantitative analysis.[9](#tca12783-bib-0009){ref-type="ref"}, [10](#tca12783-bib-0010){ref-type="ref"}, [11](#tca12783-bib-0011){ref-type="ref"}, [12](#tca12783-bib-0012){ref-type="ref"}, [13](#tca12783-bib-0013){ref-type="ref"}, [14](#tca12783-bib-0014){ref-type="ref"}, [15](#tca12783-bib-0015){ref-type="ref"}, [16](#tca12783-bib-0016){ref-type="ref"}, [17](#tca12783-bib-0017){ref-type="ref"}, [18](#tca12783-bib-0018){ref-type="ref"}, [19](#tca12783-bib-0019){ref-type="ref"}, [20](#tca12783-bib-0020){ref-type="ref"}, [21](#tca12783-bib-0021){ref-type="ref"}, [22](#tca12783-bib-0022){ref-type="ref"}, [23](#tca12783-bib-0023){ref-type="ref"}, [24](#tca12783-bib-0024){ref-type="ref"}, [25](#tca12783-bib-0025){ref-type="ref"}, [26](#tca12783-bib-0026){ref-type="ref"}, [27](#tca12783-bib-0027){ref-type="ref"}, [28](#tca12783-bib-0028){ref-type="ref"}, [29](#tca12783-bib-0029){ref-type="ref"}, [30](#tca12783-bib-0030){ref-type="ref"}, [31](#tca12783-bib-0031){ref-type="ref"}, [32](#tca12783-bib-0032){ref-type="ref"}, [33](#tca12783-bib-0033){ref-type="ref"}, [34](#tca12783-bib-0034){ref-type="ref"} Sixteen publications evaluated *P16* ^*INK4a*^ gene promoter methylation in serum and 10 in BAF/sputum. The general characteristics of the 26 studies are shown in Table [1](#tca12783-tbl-0001){ref-type="table"}.

###### 

Study characteristics

                                                                                             Distribution                  
  ------------------------------------------------------------ ------ -------- ----- ----- -------------- ---- ----- ----- ------------
  Kersting *et al*.[9](#tca12783-bib-0009){ref-type="ref"}     2000   US          31    25             18    7    13    18 Serum
  Bearzatto *et al*.[10](#tca12783-bib-0010){ref-type="ref"}   2002   Italy       30    15             12    0    18    15 Serum
  Wu *et al*.[11](#tca12783-bib-0011){ref-type="ref"}          2002   China       14    26              4    0    10    26 Serum
  Cai *et al*.[12](#tca12783-bib-0012){ref-type="ref"}         2003   China       49    55             15    1    34    54 Serum
  Kim *et al*.[13](#tca12783-bib-0013){ref-type="ref"}         2004   Korea       85   127             14    8    71   119 Serum
  Fujiwara *et al*.[14](#tca12783-bib-0014){ref-type="ref"}    2005   US         111    80             14    3    97    77 Serum
  Kong *et al*.[15](#tca12783-bib-0015){ref-type="ref"}        2007   China       64    46             19    0    45    46 Serum
  Hsu *et al*.[16](#tca12783-bib-0016){ref-type="ref"}         2007               51    33             21    3    30    30 Serum
  Zhang *et al*.[17](#tca12783-bib-0017){ref-type="ref"}       2008   China       95    22             52    2    43    20 Serum
  Ma *et al*.[18](#tca12783-bib-0018){ref-type="ref"}          2009   China       62    19             32    0    30    19 Serum
  Hu *et al*.[19](#tca12783-bib-0019){ref-type="ref"}          2009   China       46    21             22    1    24    20 Serum
  Chen *et al*.[20](#tca12783-bib-0020){ref-type="ref"}        2010   China      159    81             39    0   120    81 Serum
  Wang *et al*.[21](#tca12783-bib-0021){ref-type="ref"}        2016   China       50    50             22    0    28    50 Serum
  Wan *et al*.[22](#tca12783-bib-0022){ref-type="ref"}         2017   China       98    60             69    9    29    51 Serum
  Liu *et al*.[23](#tca12783-bib-0023){ref-type="ref"}         2017   China      120    46             45    3    75    43 Serum
  Destro *et al*.[24](#tca12783-bib-0024){ref-type="ref"}      2004   Italy       24   100             16    4     8    96 BAF/sputum
  Konno *et al*.[25](#tca12783-bib-0025){ref-type="ref"}       2004   Japan       78    94             44   20    34    74 BAF/sputum
  Wang *et al*.[26](#tca12783-bib-0026){ref-type="ref"}        2004   China       34    21             11    0    23    21 BAF/sputum
  Georgiou *et al*.[27](#tca12783-bib-0027){ref-type="ref"}    2007   Greece      80    40             55    9    25    31 BAF/sputum
  Liu *et al*.[28](#tca12783-bib-0028){ref-type="ref"}         2008   China       58   107             41   55    17    52 BAF/sputum
  Zhang *et al*.[29](#tca12783-bib-0029){ref-type="ref"}       2004   China       44    20             27    3    17    17 BAF/sputum
  Guo *et al*.[30](#tca12783-bib-0030){ref-type="ref"}         2008   China      100    50             61    0    39    50 BAF/sputum
  Hu *et al*.[31](#tca12783-bib-0031){ref-type="ref"}          2009   China       42    25             20    0    22    25 BAF/sputum
  Peng *et al*.[32](#tca12783-bib-0032){ref-type="ref"}        2010   China       82    25             60    0    22    25 BAF/sputum
  Zhang *et al*.[33](#tca12783-bib-0033){ref-type="ref"}       2012   China       41    15             21    2    20    13 BAF/sputum
  Sun *et al*.[34](#tca12783-bib-0034){ref-type="ref"}         2012   China      120   120             56    6    64   114 BAF/sputum

BAF, bronchoalveolar fluid; fn, false negative; fp, false positive; NSCLC, non‐small cell lung cancer; tn, true negative; tp, true positive; US, United States.

Pooled sensitivity and specificity {#tca12783-sec-0012}
----------------------------------

Because of significant statistical heterogeneity, the diagnostic sensitivity and specificity were pooled using the random effects method. The pooled sensitivity and specificity were 0.46 (95% confidence interval \[CI\] 0.43--0.48) (Fig [2](#tca12783-fig-0002){ref-type="fig"}) and 0.90 (95% CI 0.88--0.91) (Fig [3](#tca12783-fig-0003){ref-type="fig"}), respectively, for *P16* ^*INK4a*^ gene promoter methylation as a biomarker for the diagnosis of NSCLC.

![Forest plot if the sensitivity of *P16* ^*INK4a*^ gene promoter methylation as a biomarker for the diagnosis of non‐small cell lung cancer. CI, confidence interval.](TCA-9-1032-g010){#tca12783-fig-0002}

![Forest plot for specificity of *P16* ^*INK4a*^ gene promoter methylation as a biomarker for the diagnosis of non‐small cell lung cancer. CI, confidence interval.](TCA-9-1032-g006){#tca12783-fig-0003}

Pooled positive and negative likelihood ratios {#tca12783-sec-0013}
----------------------------------------------

The diagnostic positive likelihood ratio (+LR) and negative likelihood ratio (−LR) were also pooled by random effect method because of significant heterogeneity. The pooled +LR and −LR were 6.33 (95% CI 3.89--10.30) (Fig [4](#tca12783-fig-0004){ref-type="fig"}) and 0.57 (95% CI 0.50--0.65) (Fig [5](#tca12783-fig-0005){ref-type="fig"}), respectively, for *P16* ^*INK4a*^ gene promoter methylation as a biomarker for the diagnosis of NSCLC.

![Forest plot of the negative likelihood ratio (LR). CI, confidence interval.](TCA-9-1032-g007){#tca12783-fig-0004}

![Forest plot of the positive likelihood ratio (LR). CI, confidence interval.](TCA-9-1032-g008){#tca12783-fig-0005}

Pooled diagnostic odds ratio {#tca12783-sec-0014}
----------------------------

The pooled diagnostic odds ratio (DOR) was 10.72 (95% CI 6.94--16.56) for *P16* ^*INK4a*^ gene promoter methylation as a biomarker for the diagnosis of NSCLC (Fig [6](#tca12783-fig-0006){ref-type="fig"}).

![Forest plot of the diagnostic odds ratio (OR).](TCA-9-1032-g005){#tca12783-fig-0006}

Symmetric receiver operating characteristic curve {#tca12783-sec-0015}
-------------------------------------------------

The area under the SROC curve was 0.75 with a standard error of 0.004 for *P16* ^*INK4a*^ gene promoter methylation as a biomarker for the diagnosis of lung cancer (Fig [7](#tca12783-fig-0007){ref-type="fig"}).

![The pooled symmetric receiver operating characteristic (SROC) curve for *P16* gene promoter methylation for the diagnosis of non‐small cell lung cancer. AUC, area under the curve; SE, standard error.](TCA-9-1032-g001){#tca12783-fig-0007}

Subgroup analysis {#tca12783-sec-0016}
-----------------

We also conducted subgroup analysis, detecting *P16* ^*INK4a*^ gene promoter methylation in serum or BAF/sputum. The pooled diagnostic performances in serum and BAF/sputum are shown in Table [2](#tca12783-tbl-0002){ref-type="table"}.

###### 

Diagnostic performance in subgroup analysis

                 Serum   BAF/sputum                                 
  ------------- ------- ------------- ------- ------- ------------- -------
  Sensitivity    0.37    0.34--0.40    89.8%   0.59    0.55--0.62    71.7%
  Specificity    0.95    0.93--0.96    72.5%   0.84    0.81--0.87    93.1%
  +LR            5.46    3.43--8.69    39.6%   6.15    2.81--13.46   89.6%
  −LR            0.64    0.57--0.73    86.9%   0.49    0.51--0.57    64.2%
  DOR            9.41    5.67--15.62   32.5%   12.32   5.86--25.94   73.0%
  AUC            0.78    0.74--0.82     ---    0.71    0.69--0.77     ---

+LR, positive likelihood ratio; ‐LR, negative likelihood ratio; AUC, area under the curve; BAF, bronchoalveolar fluid; CI, confidence interval; DOR, diagnostic odds ratio.

Evaluation of publication bias {#tca12783-sec-0017}
------------------------------

Publication bias was evaluated by Egger\'s line regression test and Begg\'s funnel plot. No publication bias was detected by line regression test (*t* = 0.95; *P* = 0.35) or Begg\'s funnel plot (Fig [8](#tca12783-fig-0008){ref-type="fig"}).

![A funnel plot of publication evaluation. ESS, effective sample size. (![](TCA-9-1032-g004.jpg "image")) Study and (![](TCA-9-1032-g003.jpg "image")) Regression lines.](TCA-9-1032-g002){#tca12783-fig-0008}

Discussion {#tca12783-sec-0018}
==========

In China, lung cancer is the most commonly diagnosed malignant carcinoma and the leading cause of cancer mortality in both men and women, particularly in men aged ≥ 75 years. As most NSCLC patients are only diagnosed at locally advanced‐stage or after remote metastasis has occurred, they are ineligible for surgery. Prognosis is poor, with an extremely low five‐year survival rate, because of the lack of effective methods for lung cancer screening or early diagnosis.

Promoter methylation of tumor suppressor genes is common in body fluid and can be used as a lung cancer diagnosis method or biomarker. Several studies have evaluated its clinical application with acceptable diagnostic performance and high specificity.[35](#tca12783-bib-0035){ref-type="ref"}, [36](#tca12783-bib-0036){ref-type="ref"}, [37](#tca12783-bib-0037){ref-type="ref"}, [38](#tca12783-bib-0038){ref-type="ref"}

The *P16* ^*INK4a*^ gene, also known as the *CDKN2A* gene, is located on chromosome 9 (9p21.3) and plays an important role in regulating the cell cycle.[39](#tca12783-bib-0039){ref-type="ref"} The promoter region of *P16* ^*ink4a*^ is usually hypermethylated in cancer cells of NSCLC patients. Studies have found that *P16* ^*INK4a*^ methylation can be detected in body fluid, such as serum and sputum,[23](#tca12783-bib-0023){ref-type="ref"}, [24](#tca12783-bib-0024){ref-type="ref"} indicating that detection of *P16* ^*INK4a*^ methylation status may be used as an important tool for lung cancer diagnosis, screening, or the monitoring of recurrence.

Two previous meta‐analyses evaluated *P16* ^*INK4a*^ methylation in serum and sputum as a biomarker for lung cancer diagnosis and concluded that detection of *P16* ^*INK4a*^ promoter methylation via these methods was a useful tool for lung cancer diagnosis.[40](#tca12783-bib-0040){ref-type="ref"}, [41](#tca12783-bib-0041){ref-type="ref"} However, several recently published relevant studies were not included in these meta‐analyses. Therefore, we performed an updated meta‐analysis, including recently published relevant publications and further evaluated the clinical value of *P16* ^*INK4a*^ methylation as a biomarker for NSCLC diagnosis. We confirmed that *P16* ^*INK4a*^ gene promoter methylation detection in serum or BAF/sputum may be a potential biomarker for NSCLC diagnosis; however, the sensitivity was relatively low and was thus not suitable for NSCLC screening.

Although our results indicate that *P16* ^*INK4a*^ gene promoter methylation represents a promising method for NSCLC diagnosis, there was significant statistical heterogeneity in the process of data merging, which inevitably affected our results. Furthermore, the sample sizes of the included studies were relatively small, which can reduce the statistical power of each included study. Large‐scale prospective diagnostic tests should be conducted by multiple health centers to further evaluate the clinical application value of *P16* ^*INK4a*^ gene promoter methylation as an NSCLC diagnostic method.
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